27 December 2002
Autoantibodies in children with chronic hepatitis B undergoing interferon therapy.
Irma Kacprzak-Bergman, Izabela Zaleska, Jarosław Gruszka, Ernest KucharMed Sci Monit 2002; 8(12): CR821-824 :: ID: 4805
Abstract
BACKGROUND: The occurrence of various side effects in patients treated with interferon alpha has attracted more attention to the manifestation of autoantibodies. The purpose of our study was to evaluate the side effects of interferon in children suffering from chronic hepatitis B by detecting six autoantibodies. MATERIAL/METHODS: Autoantibodies were examined in 76 children (55 boys and 21 girls) aged 2-16 years, treated with interferon-alpha 3 MU 3 times weekly for 20 weeks. They were tested before treatment (exam I) and after its conclusion (exam II). SMAs were determined by indirect immunofluorescence (Euroimmuno reagents), while ANA, AMA M2, GPC, TPO and ATG were measured by EIA (Biomedica reagents). RESULTS: No statistically significant differences were found between the total number of patients with autoantibodies in examination I and examination II. A comparison of the frequency of presence or absence of autoantibodies in the same patients in exams I and II showed significantly more frequent disappearance of GPC in exam II than appearance (p<0.00005). This was also observed in the case of TPO (p=0.320). In relation to ANA, SMA, AMA M2 and ATG these differences were not significant. CONCLUSIONS: INF-alpha does not induce autoantibody formation in children with chronic hepatitis B. Our results suggest that IFN-alpha may inhibit the formation of some autoantibodies.
Keywords: Hepatitis B, Chronic - drug therapy, Hepatitis B, Chronic - immunology, Interferon Type I, Recombinant - adverse effects, Interferon Type I, Recombinant - therapeutic use, Iodide Peroxidase - immunology, Mitochondria - immunology, Parietal Cells, Gastric - immunology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952